Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases

Autor: Ponlatham Chaiyarit, Siriporn Proungvitaya, Temduang Limpaiboon, Wiphawan Wasenang
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
medicine.medical_specialty
lcsh:QH426-470
Misdiagnosis
MS-HRM
lcsh:Medicine
GPI-Linked Proteins
Gastroenterology
Cholangiocarcinoma
Diagnosis
Differential
03 medical and health sciences
Cell-free DNA
0302 clinical medicine
Internal medicine
Genetics
medicine
Humans
Molecular Biology
Genetics (clinical)
Homeodomain Proteins
DNA methylation
Receiver operating characteristic
Bile duct
business.industry
Differential biomarker
Research
lcsh:R
fungi
Cancer
Methylation
medicine.disease
Neoplasm Proteins
lcsh:Genetics
030104 developmental biology
medicine.anatomical_structure
Bile Ducts
Intrahepatic
Cell-free fetal DNA
Bile Duct Neoplasms
030220 oncology & carcinogenesis
Biomarker (medicine)
Differential diagnosis
business
Cell Adhesion Molecules
Cell-Free Nucleic Acids
Biomarkers
Developmental Biology
Zdroj: Clinical Epigenetics
Clinical Epigenetics, Vol 11, Iss 1, Pp 1-10 (2019)
ISSN: 1868-7083
1868-7075
Popis: Background Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct epithelial cell lining. The misdiagnosis of CCA and other biliary diseases may occur due to the similarity of clinical manifestations and blood tests resulting in inappropriate or delayed treatment. Thus, an accurate and less-invasive method for differentiating CCA from other biliary diseases is inevitable. Methods We quantified methylation of OPCML, HOXA9, and HOXD9 in serum cell-free DNA (cfDNA) of CCA patients and other biliary diseases using methylation-sensitive high-resolution melting (MS-HRM). Their potency as differential biomarkers between CCA and other biliary diseases was also evaluated by using receiver operating characteristic (ROC) curves. Results The significant difference of methylation levels of OPCML and HOXD9 was observed in serum cfDNA of CCA compared to other biliary diseases. Assessment of serum cfDNA methylation of OPCML and HOXD9 as differential biomarkers of CCA and other biliary diseases showed the area under curve (AUC) of 0.850 (0.759–0.941) for OPCML which sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 80.00%, 90.00%, 88.88%, 81.81%, and 85.00%, respectively. The AUC of HOXD9 was 0.789 (0.686–0.892) with sensitivity, specificity, PPV, NPV, and accuracy of 67.50%, 90.00%, 87.09%, 73.46%, and 78.75%, respectively. The combined marker between OPCML and HOXD9 showed sensitivity, specificity, PPV, and NPV of 62.50%, 100%, 100%, and 72.72%, respectively, which may be helpful to prevent a misdiagnosis between CCA and other biliary diseases. Conclusions Our findings suggest the application of serum cfDNA methylation of OPCML and HOXD9 for differential diagnosis of CCA and other biliary diseases due to its less invasiveness and clinically practical method which may benefit the patients by preventing the misdiagnosis of CCA and avoiding unnecessary surgical intervention. Electronic supplementary material The online version of this article (10.1186/s13148-019-0634-0) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: